site-logo
  • LiquidHALLMARK®
  • Multi-Cancer Screening
  • Resources
    • Publications
    • News & Events
  • Patients
  • Company
    • About Us
    • News & Events
    • Careers
    • Contact Us
  • Portal Login

News & Update: News

Lucence Demonstrates Combined ctDNA and ctRNA Liquid Biopsy Improves Diagnostic Yield at ASCO 2025

Lucence Demonstrates Combined ctDNA and ctRNA Liquid Biopsy Improves Diagnostic Yield at ASCO 2025

Agilus Diagnostics and Lucence Announce Strategic Collaboration to Advance Cancer Testing Services in India

Agilus Diagnostics and Lucence Announce Strategic Collaboration to Advance Cancer Testing Services in India

Mayo Clinic Laboratories and Lucence announce strategic collaboration to enhance cancer testing services

Mayo Clinic Laboratories and Lucence announce strategic collaboration to enhance cancer testing services

Lucence Secures MolDX Approval for LiquidHALLMARK® ctDNA and ctRNA Liquid Biopsy Test to Advance Non-Invasive Cancer Diagnostics

Lucence Secures MolDX Approval for LiquidHALLMARK® ctDNA and ctRNA Liquid Biopsy Test to Advance Non-Invasive Cancer Diagnostics

Lucence Announces Expanded Access for LiquidHALLMARK® Liquid Biopsy Test Through Participation Across Regence Plans

Lucence Announces Expanded Access for LiquidHALLMARK® Liquid Biopsy Test Through Participation Across Regence Plans

Lucence and Diagnostics Development Hub (DxD Hub) Collaborate on Expanding Multi-Cancer Early Detection Testing to Alternative Sample Types

Lucence and Diagnostics Development Hub (DxD Hub) Collaborate on Expanding Multi-Cancer Early Detection Testing to Alternative Sample Types

Lucence Showcases Liquid Biopsy Tech for Earlier Cancer Detection at 2024 ASCO Annual Meeting

Lucence Showcases Liquid Biopsy Tech for Earlier Cancer Detection at 2024 ASCO Annual Meeting

Lucence Confirms Comprehensive Medicare Coverage for LiquidHALLMARK® and Demonstrates Sensitive Detection of Lung Cancer Biomarkers in Prospective Study

Lucence Confirms Comprehensive Medicare Coverage for LiquidHALLMARK® and Demonstrates Sensitive Detection of Lung Cancer Biomarkers in Prospective Study

Interim Results from LIQUIK Prospective Study Released at WCLC 2023

Interim Results from LIQUIK Prospective Study Released at WCLC 2023

Lucence Announces CPT PLA Code Granted to LiquidHALLMARK®

Lucence Announces CPT PLA Code Granted to LiquidHALLMARK®

Posts navigation

Older posts
Up arrow Back to top
Footer logo
Reach Us
3520 W Bayshore Road, Palo Alto, CA 94303 [email protected] (888) 582 3623
Subscribe for Updates

    Follow Us
    • facebook facebook-white
    • linkedin linkedin-white
    • twitter twitter-white

    © 2025 Lucence Health Inc. All rights reserved. All logos and trademarks are the property of Lucence or their respective owners.

    LiquidHALLMARK® | AmpliMark™ | Publications | Careers | About | Privacy

    • Order Terms
    • Website Terms of Use

    Mayo Clinic Laboratories and Lucence announce strategic collaboration to enhance cancer testing services

    >

    Lucence Demonstrates Combined ctDNA and ctRNA Liquid Biopsy Improves Diagnostic Yield at ASCO 2025

    >